Chronic Pain Management Techniques from OUD with Integrative Care

Explore integrative care for OUD and chronic pain and discover holistic methods to manage your health effectively.

Abstract

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this comprehensive educational post, I guide you through a clinically grounded, easy-to-follow journey that explains how and why we use medications for opioid use disorder (OUD) — especially buprenorphine, methadone, and naltrexone — alongside integrative chiropractic care, functional medicine, rehabilitation, and personal injury services. I describe the physiology of the mu-opioid receptor, the life-saving value of medications for OUD, and the practical realities of initiating buprenorphine in the fentanyl era using traditional, low-dose microdosing, and high-dose macrodosing strategies. I also explain the roles of long-acting injectable buprenorphine (Sublocade and Brixadi), special-population considerations (pregnancy, perioperative care, adolescents), and safe continuation or transition protocols.

I practice at Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, within a multidisciplinary, integrative model common in rehabilitation and injury care clinics. I work closely with Dr. Maria Guadalupe Cardenas, MD — Board Certified in Internal Medicine (NPI #1164426749, Texas MD License #J2933) — who has over 40 years of experience and serves as our Medical Director and Collaborative Physician. Together, we integrate medical oversight, chiropractic care, functional medicine, rehabilitation, and harm reduction to improve safety, function, and quality of life.

Throughout this post, I present up-to-date insights from leading researchers and national guidelines, explain the neurobiological underpinnings in plain language, and show how integrative chiropractic care fits into a compassionate, evidence-based plan for OUD and chronic pain. I include clinical observations from my practice and public educational materials at https://pushasrx.com/ and https://www.linkedin.com/in/dralexjimenez/. References are cited in APA-7 style with hyperlinked titles so you can explore the source materials.

About Our Multidisciplinary Team and Integrative Care Model

• I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. My work spans integrative chiropractic care, advanced practice nursing, functional medicine, rehabilitation, and personal injury care.
• I practice at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas.
• Our Medical Director and Collaborative Physician is Dr. Maria Guadalupe Cardenas, MD:

• • Board-certified in Internal Medicine
  • NPI #1164426749
  • Texas MD License #J2933
  • Over 40 years of clinical experience

• This is a common integrative or injury clinic structure: an MD provides medical direction and oversight alongside a chiropractor and allied clinicians.
• We coordinate:

• • Medical management for OUD and complex comorbidities
  • Integrative chiropractic care for neuromusculoskeletal dysfunction and pain modulation
  • Functional medicine for inflammation, metabolism, gut-brain axis, sleep, and micronutrient status
  • Rehabilitation and personal injury care for mechanical restoration, motor control, and return to function
  • Harm reduction and continuity planning for safety and retention in care

Why I Care: The Realities Patients Bring Into Our Clinic

In my clinic, patients rarely present with a single problem. I often meet individuals with overlapping issues such as low back pain, neck pain, sciatica, post-traumatic pain after collisions, headaches, sleep disruption, medication dependence, opioid tolerance, fear of withdrawal, functional decline, mood changes, work limitations, and loss of confidence in movement.

When chronic pain overlaps with opioid exposure and OUD, the picture becomes complex:

• Pain encourages opioid use.
• Opioid tolerance and dependence emerge.
• Withdrawal amplifies pain sensitivity.
• Fear of pain reduces movement.
• Reduced movement stiffens joints, weakens muscles, alters gait, and increases disability.

I organize care around the whole person. I ask:

• What is driving this patient’s pain — nerve compression, joint dysfunction, soft-tissue injury, inflammation, metabolic dysfunction, or central sensitization?
• Is the patient experiencing withdrawal, cravings, tolerance, or dependence?
• Does the patient meet criteria for OUD?
• Is medication-assisted treatment appropriate?
• How can chiropractic care and rehabilitation be applied safely?
• What medical oversight is needed?
• How can I reduce harm while restoring function?

Why Medications for Opioid Use Disorder Save Lives

The strongest evidence shows that medications for OUD — especially buprenorphine and methadone — reduce mortality, improve retention, and decrease illicit opioid use. These therapies stabilize physiology and give patients the breathing room to engage in recovery, build functioning, and live.

• OUD is not a moral failing; it is a chronic, treatable medical condition affecting reward circuitry, stress response, pain modulation, motivation, memory, and executive function.
• Stabilization reduces swings between intoxication, withdrawal, craving, and relapse that disrupt sleep, immune signaling, hormones, autonomic balance, gut function, muscle tone, inflammation, decision-making, and rehabilitation participation.

References:

• Medications for opioid use disorder save lives (National Academies of Sciences, Engineering, and Medicine, 2019)
• Medications for opioid use disorder: Treatment Improvement Protocol 63 (Substance Abuse and Mental Health Services Administration, 2021)
• ASAM national practice guideline for the treatment of opioid use disorder (American Society of Addiction Medicine, 2020)
• Opioid use disorder treatment and mortality reduction (Sordo et al., 2017)

Understanding the Mu-Opioid Receptor: Plain-Language Physiology

The mu-opioid receptor (MOR) is a protein found throughout the nervous system. It governs pain modulation, reward signaling, respiration, stress response, mood, and gastrointestinal motility. Different drugs activate (or block) this receptor in different ways.

• Full agonists (e.g., methadone, fentanyl) strongly activate MOR; as the dose increases, the effect increases up to a maximal level.
• Partial agonists (e.g., buprenorphine) activate MOR to a limited ceiling; as the dose increases, the effect plateaus.
• Antagonists (e.g., naltrexone) bind the receptor but do not activate it; they block other opioids.

References:

• Basic opioid pharmacology: An update (Pathan & Williams, 2012)
• Buprenorphine: A unique drug with complex pharmacology (Lutfy & Cowan, 2004)

Methadone as a Full Opioid Agonist: When and Why We Use It

Methadone is a full MOR agonist. Clinically, it:

• Reduces withdrawal and cravings
• Stabilizes patients with high tolerance
• Improves retention
• Reduces illicit opioid use and mortality

Because it is a full agonist, we pay close attention to:

• Respiratory depression
• Sedation and overdose
• QT interval prolongation
• Drug interactions
• Accumulation due to a long and variable half-life

Key practice points:

• Methadone for OUD is dispensed via federally regulated opioid treatment programs (OTPs) in the U.S.
• Hospital clinicians can initiate or adjust inpatient methadone; outpatient OUD methadone requires an OTP.
• The three-day rule can bridge discharge when access is delayed.
• We obtain baseline ECGs and use QTcF (Fridericia) for risk assessment; avoid initiation if QTc >500 ms unless specialist-guided.

References:

• ASAM national practice guideline for the treatment of opioid use disorder (American Society of Addiction Medicine, 2020)
• VA/DoD clinical practice guideline for the use of opioids in the management of chronic pain (Department of Veterans Affairs & Department of Defense, 2022)

Buprenorphine as a Partial Agonist: Safety Ceiling, Stabilization, and Clinical Value

Buprenorphine partially activates MOR and has:

• High receptor affinity
• Slow dissociation
• A ceiling effect for respiratory depression
• Long duration of action

Clinical advantages:

• Lower overdose risk compared with full agonists
• Reduces withdrawal and cravings
• Can block or blunt effects of other opioids
• Useful for OUD and, in selected cases, chronic pain

We watch for precipitated withdrawal if buprenorphine is started too soon after full agonist use. The high affinity of buprenorphine can displace a full agonist and abruptly lower net receptor activation, producing sudden, severe withdrawal.

References:

• Medications for opioid use disorder: Treatment Improvement Protocol 63 (SAMHSA, 2021)
• Buprenorphine: A unique drug with complex pharmacology (Lutfy & Cowan, 2004)

Naltrexone as an Antagonist: Narrow Role and Special Considerations

Naltrexone blocks opioid receptors without activating them.

• Blocks euphoria and analgesia from opioids
• Requires complete detoxification before initiation, or it triggers withdrawal.l
• Not used for opioid analgesia
• May complicate acute pain management during emergencies

Appropriate for highly motivated patients preferring abstinence-based strategies with strong supports and lower cravings.

References:

• ASAM national practice guideline for the treatment of opioid use disorder (ASAM, 2020)
• WHO guidelines for the psychosocially assisted pharmacological treatment of opioid dependence (World Health Organization, 2009)

Why Behavioral Health Matters — And Why It Should Never Block Medication

Behavioral care helps with coping, motivation, trauma recovery, and family dynamics. But evidence-based medications should never be withheld when someone is not ready for counseling. We practice harm reduction and meet patients where they are:

• What helps reduce risk today?
• What is the patient ready to try now?
• How do we keep the door open?

References:

• Medications for opioid use disorder save lives (National Academies, 2019)
• CDC clinical practice guideline for prescribing opioids for pain: United States, 2022 (Dowell et al., 2022)

Buprenorphine Formulations for OUD and Pain

For OUD:

• Buprenorphine sublingual tablets
• Buprenorphine-naloxone sublingual films or tablets
• Long-acting injectables: Sublocade, Brixadi

For pain:

• Butrans transdermal patch
• Belbuca buccal film
• Buprenex injectable (usually in acute settings)

In complex chronic pain with opioid dependence or high risk, sublingual buprenorphine may be used off-label under careful medical oversight.

References:

• Medications for opioid use disorder: Treatment Improvement Protocol 63 (SAMHSA, 2021)
• CDC clinical practice guideline for prescribing opioids for pain: United States, 2022 (Dowell et al., 2022)

Why Some Formulations Combine Buprenorphine With Naloxone

Buprenorphine-naloxone products discourage injection misuse. When dissolved sublingually as directed, naloxone has limited bioavailability; if injected, it can precipitate withdrawal. If patients cannot tolerate combination products (e.g., due to oral irritation or taste), consider a buprenorphine-only product, with attention to coverage constraints and safe continuity.

References:

• Medications for opioid use disorder: Treatment Improvement Protocol 63 (SAMHSA, 2021)

How I Teach Patients to Take Sublingual Buprenorphine

• Place the film or tablet under the tongue and let it fully dissolve (often about 10 minutes).
• Do not chew or swallow the medication whole.
• Avoid eating or drinking during dissolution.
• Practice careful dental hygiene after dosing and report mouth sores or persistent nausea.
• If nausea occurs from swallowed saliva, spitting out excess saliva after dissolution may help.

References:

• FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain (U.S. Food and Drug Administration, 2022)

Dental Health and Sublingual or Buccal Buprenorphine

Transmucosal buprenorphine has been associated with dental issues such as caries. I do not discourage life-saving therapy; instead, I provide prevention tips:

• Rinse the mouth with water after dosing.
• Wait a bit before brushing to avoid enamel irritation.
• Schedule regular dental visits and use fluoride toothpaste.
• Report dental pain early.
• Manage dry mouth and avoid sugary beverages.

Reference:

• FDA warns about dental problems with buprenorphine medicines dissolved in the mouth (FDA, 2022)

Informed Consent Before Starting Buprenorphine

My informed consent discussions include:

• Buprenorphine is an opioid and can cause physical dependence.
• It reduces cravings and withdrawal and lowers overdose risk compared with untreated OUD.
• Do not mix with alcohol, sedatives, or benzodiazepines unless medically supervised.
• Common side effects include constipation, sweating, nausea, sedation, and headache.
• Safe storage is essential.
• Transmucosal use may have dental risks; we will mitigate them.

References:

• Medications for opioid use disorder: Treatment Improvement Protocol 63 (SAMHSA, 2021)

Precipitated Withdrawal: What It Is, Why It Happens, and How We Prevent It

Precipitated withdrawal occurs when buprenorphine displaces a full agonist (e.g., fentanyl) from MOR but only partially activates the receptor. The net receptor stimulation abruptly decreases, triggering sudden, intense withdrawal symptoms.

Typical signs and symptoms:

• Severe aches, nausea, vomiting, diarrhea
• Sweating, anxiety, restlessness
• Piloerection (gooseflesh), dilated pupils
• Abdominal cramping, rapid heart rate, intense cravings

Prevention:

• In traditional induction, start buprenorphine when the patient is in clearly established withdrawal.
• In fentanyl contexts, we consider low-dose microdosing or high-dose supervised initiation to match real-world pharmacokinetics and patient preference.
• Always practice shared decision-making.

References:

• Medications for opioid use disorder: Treatment Improvement Protocol 63 (SAMHSA, 2021)
• ASAM national practice guideline for the treatment of opioid use disorder (ASAM, 2020)

The Fentanyl Era: Why Initiation Is Different Today

Illicitly manufactured fentanyl is potent and lipophilic, distributing into fat tissue and leaching over time. Even after waiting 48–72 hours, enough fentanyl may remain to precipitate withdrawal when buprenorphine is started, particularly at higher initial doses.

Common patient-reported features in fentanyl withdrawal:

• Severe internal restlessness (akathisia-like)
• Intense anxiety, depression, and hopelessness

Because many patients have experienced precipitated withdrawal previously, I emphasize empathy, shared decision-making, and flexible initiation options.

References and clinical considerations:

• ASAM national practice guideline for the treatment of opioid use disorder (ASAM, 2020)

Three Approaches to Buprenorphine Initiation: Traditional, Low-Dose Microdosing, and High-Dose Macrodosing

I select among three strategies based on patient preference, clinical setting, risk tolerance, and fentanyl exposure:

• Traditional initiation (withdrawal-based, 2–4 mg start)
• Low-dose microdosing initiation (overlap without withdrawal)
• High-dose macrodosing initiation (rapid stabilization in supervised settings)

I rely on the Clinical Opioid Withdrawal Scale (COWS) and, crucially, the patient’s subjective experience to guide timing and dosing. Adjunct medications for comfort may include clonidine, tizanidine, hydroxyzine, trazodone, NSAIDs/acetaminophen, ondansetron, and loperamide when appropriate.

References and practice guides:

• California Bridge. Buprenorphine Quick Start
• ASAM national practice guideline for the treatment of opioid use disorder (ASAM, 2020)

Method 1: Traditional Buprenorphine Initiation

When I use it:

• Short-acting prescription opioid transitions
• Selected cases without fentanyl exposure
• Patients who prefer a familiar method and can tolerate withdrawal

Protocol overview:

• Abstain according to prior opioid (12–24 hours for short-acting; 24–72 for long-acting; 48+ for fentanyl, often longer).
• Confirm mild to moderate withdrawal (COWS ≥8–12).
• Start 2–4 mg sublingual; observe 1–2 hours; titrate by 2–4 mg every 2–4 hours as needed, targeting 12–16 mg on day 1.

Pros:

• Simple dosing; well-known for non-fentanyl opioids.

Cons in fentanyl era:

• Higher risk of precipitated withdrawal
• Often underdoses the initial need for high-tolerance fentanyl users
• Abstinence period is a major barrier

References:

• Medications for opioid use disorder: Treatment Improvement Protocol 63 (SAMHSA, 2021)

Method 2: Low-Dose Buprenorphine Microdosing (Overlap Initiation)

When I use it:

• Patients with fentanyl exposure
• Patients with strong fear of withdrawal
• Patients with chronic pain who need continuous analgesia during transition
• Outpatient settings with high-touch support

Rationale:

• Start with very small buprenorphine doses (e.g., 0.25–0.5 mg) while the patient continues a reduced amount of full agonist.
• Gently increase buprenorphine over days while tapering the full agonist.
• Transition to a full buprenorphine dose once enough receptor occupancy is achieved.
• Goal: avoid precipitated withdrawal and minimize discomfort.

Practical notes:

• Requires careful film or tablet splitting and clear instructions.
• Ongoing illicit use during overlap requires robust harm reduction counseling.
• Strong care coordination and frequent check-ins increase success.

Benefits:

• Patient-preferred due to comfort
• Ideal for maintaining function in complex pain

Challenges:

• Complexity of dosing
• Continued risk during overlap period
• Outpatient success depends on support network

References:

• California Bridge. Buprenorphine Quick Start
• ASAM national practice guideline for the treatment of opioid use disorder (ASAM, 2020)

Method 3: High-Dose Buprenorphine Macrodosing (Supervised Rapid Stabilization)

When I use it:

• Emergency department or urgent care environments
• Outpatient settings with same-day supervision for motivated patients
• Fentanyl exposure with clear, objective moderate withdrawal

Protocol:

• Ensure at least 12 hours since last fentanyl use.
• Confirm COWS >16 and at least two objective signs: dilated pupils, piloerection, rhinorrhea, diarrhea.
• Administer 16 mg buprenorphine as an initial dose; monitor for 30–60 minutes.
• If tolerated and helpful, consider an additional 8 mg up to 32 mg on day 1.
• Day 2: continue 24–32 mg daily as needed for stabilization.

Pros:

• Rapid relief and stabilization
• Simple dosing without cutting films

Cons:

• Risk of severe precipitated withdrawal if the patient is not far enough into withdrawal
• Requires clinical observation capacity

References:

• California Bridge. Buprenorphine Quick Start
• ASAM national practice guideline for the treatment of opioid use disorder (ASAM, 2020)

Dose Realities in the Fentanyl Era: Why Higher Buprenorphine Doses May Be Appropriate

For patients with sustained fentanyl exposure, stabilization sometimes requires more than the historical 16–24 mg/day. In selected cases, doses up to 32 mg/day may be clinically justified with careful monitoring and documentation. Advocacy for insurance coverage is often necessary. We always individualize dosing to balance symptom control, safety, and function.

Reference context:

• ASAM national practice guideline for the treatment of opioid use disorder (ASAM, 2020)

Long-Acting Injectable Buprenorphine: Sublocade and Brixadi

Why I consider injectables:

• Flatten peaks and troughs to reduce cravings and withdrawal waves
• Improve adherence by removing daily dosing decisions
• Support retention and function

Sublocade:

• Typically 300 mg or 100 mg dosing; steady state occurs over 4–6 months.
• Requires prior tolerance to at least 8 mg sublingual buprenorphine.
• Supplemental sublingual dosing may be needed early in treatment.

Brixadi:

• Weekly and monthly options enable flexible initiation and continuation.
• In ED or urgent care settings, weekly initiation can help with rapid linkage to community care.
• Serum levels may fall near the end of the cycle until steady state; occasional supplements can help.

Considerations:

• Injection site reactions
• Cost and coverage
• Clinic logistics and staff training

References:

• Medications for opioid use disorder: Treatment Improvement Protocol 63 (SAMHSA, 2021)

Special Populations: Pregnancy, Perioperative Care, and Adolescents

Pregnancy:

• Continue sublingual buprenorphine; injectables are not FDA-approved in pregnancy.
• Split dosing may be needed due to altered pharmacokinetics.
• Maintaining receptor occupancy reduces maternal stress and relapse risk.

Perioperative Care:

• Continue buprenorphine through surgery.
• Coordinate with anesthesia for multimodal analgesia and dose adjustments when needed.

Adolescents:

• Buprenorphine is FDA-approved for patients 16 and up.
• I emphasize that around 8 mg provides minimum blockade for meaningful overdose protection in many cases.
• Pair medication with family and school supports, sleep hygiene, and digital well-being strategies.

References:

• ASAM national practice guideline for the treatment of opioid use disorder (ASAM, 2020)

Methadone: Pharmacology, Safety, and Legal Framework

Pharmacology:

• Peak effect ~4 hours
• Half-life varies widely (8–65 hours); accumulation over 4–7 days even at a constant dose
• Counsel patients that effects rise due to accumulation without dose increases

Safety:

• Drug-drug interactions via CYP pathways
• QTc monitoring with QTcF (Fridericia)
• Avoid initiation if QTc >500 ms unless specialist-guided

Legal considerations (U.S.):

• Inpatient clinicians can initiate/adjust methadone
• Outpatient methadone for OUD must be dispensed via OTPs
• Three-day rule for bridging access after hospital discharge

References:

• VA/DoD clinical practice guideline for the use of opioids in the management of chronic pain (VA/DoD, 2022)
• ASAM national practice guideline for the treatment of opioid use disorder (ASAM, 2020)

Naltrexone: Antagonist Therapy With a Focused Role

• Requires an opioid-free state (7–10 days, including tramadol) before initiation
• Oral dosing commonly begins at 25 mg to reduce GI upset, then 50 mg daily
• IM Vivitrol is 380 mg every 4 weeks; some patients benefit from slightly shorter intervals
• Important to plan for pain control because naltrexone blocks opioid analgesia

References:

• WHO guidelines for the psychosocially assisted pharmacological treatment of opioid dependence (WHO, 2009)
• ASAM national practice guideline for the treatment of opioid use disorder (ASAM, 2020)

Buprenorphine for Chronic Pain: Lower Risk and Functional Gains

Why I use buprenorphine in selected pain cases:

• Partial agonism reduces risk of respiratory depression
• Lower sedation supports participation in rehabilitation
• Potentially less opioid-induced hyperalgesia
• Stabilizes receptor occupancy, smoothing daily pain fluctuations

Formulations:

• Transdermal Butrans (weekly)
• Buccal Belbuca (q12h)
• Off-label sublingual buprenorphine for higher MME transitions or complex cases

Clinical strategy:

• Determine mechanical, inflammatory, neuropathic, and central sensitization drivers
• Integrate chiropractic adjustments, soft tissue work, and neuromuscular rehabilitation
• Apply functional medicine approaches for sleep, anti-inflammatory nutrition, and micronutrients
• Use buprenorphine to create a safer analgesic platform for active recovery

References:

• CDC clinical practice guideline for prescribing opioids for pain: United States, 2022 (Dowell et al., 2022)
• Buprenorphine: A unique drug with complex pharmacology (Lutfy & Cowan, 2004)

How Integrative Chiropractic Care Fits Into OUD and Pain Treatment

My chiropractic work is not a substitute for OUD medication when indicated; it complements medication by reducing pain drivers and improving function.

What I evaluate:

• Posture, range of motion, orthopedic testing
• Neurologic screening and red flags
• Segmental dysfunction, soft-tissue restrictions, and gait mechanics
• Imaging review when appropriate

How I treat:

• Adjustments to normalize joint mechanics and reduce nociceptive input
• Myofascial release and instrument-assisted techniques for trigger points and fascial adhesions
• Neurodynamic mobilization for nerve glide and proprioceptive input
• Motor control training for core stabilization, hip/pelvic control, scapular mechanics, and balance
• Graded exposure to restore confidence in movement

Why it helps:

• Mechanical correction decreases nociceptive bombardment that sustains central sensitization
• Improved biomechanics reduce flare-ups and reliance on medications alone
• Better function improves mood, sleep, and resilience during OUD stabilization

Clinical observations:

• Patients on buprenorphine often report clearer thinking and less sedation, enabling consistent participation in rehabilitation and home exercise programs.
• Restoring movement patterns reduces fear-avoidance, improving adherence and outcomes.

Explore my clinical observations:

• https://pushasrx.com/
• https://www.linkedin.com/in/dralexjimenez/

References:

• CDC clinical practice guideline for prescribing opioids for pain: United States, 2022 (Dowell et al., 2022)

The Physiology of Pain, Central Sensitization, and Opioid Exposure

Chronic pain modifies the nervous system. Central sensitization amplifies pain response, reduces descending inhibition, expands pain fields, and heightens stress and sleep disruption. Long-term opioid exposure may contribute to opioid-induced hyperalgesia, in which patients become more sensitive to pain despite — and sometimes because of — opioid therapy.

A better care model:

• Reduce nociceptive input via mechanical corrections
• Improve sleep, reduce inflammation, and restore metabolic resilience
• Retrain the nervous system with graded movement
• Stabilize the opioid receptor system with appropriate medications

References:

• CDC clinical practice guideline for prescribing opioids for pain: United States, 2022 (Dowell et al., 2022)

Rehabilitation: Rebuilding Capacity, Confidence, and Daily Function

What I include in rehab plans:

• Mobility and stabilization exercises
• Core strengthening; hip/pelvic control; cervical and scapular stabilization
• Balance training and gait retraining
• Breathing mechanics for autonomic balance
• Neuromuscular re-education and work conditioning

Why graded exposure matters:

• Patients learn that movement is safe and productive
• Confidence returns as capacity grows
• Pain becomes less threatening, and function improves
• Essential during OUD stabilization and medication transitions

Reference:

• CDC clinical practice guideline for prescribing opioids for pain: United States, 2022 (Dowell et al., 2022)

Functional Medicine in OUD and Pain: Systems That Shape Recovery

I assess and address:

• Inflammation, insulin resistance, and nutrient status (e.g., vitamin D, magnesium, omega-3s)
• Gut-brain axis and GI health
• Sleep quality and stress physiology
• Hormonal balance and mitochondrial function
• Body composition and cardiometabolic risk

Why this matters:

• Pain perception, coping, energy, and mood are profoundly influenced by systemic biology
• Optimizing these systems improves participation in rehab and stability in OUD treatment

Harm Reduction: Compassionate, Practical Safety

I normalize naloxone access and overdose education for anyone using or exposed to opioids. Harm reduction is not permissive; it is protective. It includes:

• Naloxone training and distribution
• Safer use education and fentanyl test strips where legal
• Avoiding use alone
• Awareness of respiratory depressant combinations
• Syringe service programs and infectious disease screening
• Hepatitis C and HIV referrals
• MOUD access and nonjudgmental communication

Reference:

• Medications for opioid use disorder save lives (National Academies, 2019)

Respiratory Depression Risk: Alcohol, Benzodiazepines, and Other CNS Depressants

Even with buprenorphine’s ceiling effect, mixing with sedatives can be dangerous. I provide clear counseling:

• Avoid alcohol and benzodiazepines unless medically supervised
• Be vigilant with sleep medications, muscle relaxants, sedating antihistamines, and gabapentinoids
• Carry naloxone and ensure family knows how to use it

References:

• Medications for opioid use disorder: Treatment Improvement Protocol 63 (SAMHSA, 2021)

Liver Function and Buprenorphine

The liver metabolizes Buprenorphine. In patients with hepatic impairment or alcohol use, I monitor enzymes and adjust care. Dr. Cardenas provides medical oversight to ensure appropriate labs, safety monitoring, and shared decisions for complex cases.

Shared Decision-Making: Honoring Patient Goals and Context

I involve patients in every step:

• Explaining the diagnosis and treatment options
• Reviewing risks and benefits
• Aligning dosing approaches with values and lifestyle
• Planning for follow-up and adjustments
• Respecting prior experiences, including fear of precipitated withdrawal

Coordinating Chiropractic Care With Medication Treatment

Timing matters. Aggressive manual therapy during acute withdrawal is unhelpful. We stabilize first. Once stable, I integrate chiropractic adjustments, myofascial care, and rehab matched to the patient’s tolerance, sleep, and overall medical plan. We proactively communicate red flags that require immediate medical evaluation.

Clinical Observations From My Integrated Practice

What I commonly see:

• With buprenorphine stabilization, patients think more clearly and participate more consistently in rehab.
• Mechanical corrections reduce flare-ups, lower needed opioid doses, and improve function.
• Functional medicine improvements in sleep, nutrition, and inflammation yield tangible pain reductions and increased resilience.

Explore my observations:

• https://pushasrx.com/
• https://www.linkedin.com/in/dralexjimenez/

Personal Injury Care: Acute Trauma Without Long-Term Opioid Dependence

Common post-injury pain patterns:

• Neck and low back pain, headaches, shoulder and hip pain
• Sciatica, radicular pain, muscle spasm, ligament sprains, disc irritation
• Dizziness, sleep disruption, fear of driving or movement

Conservative care:

• Chiropractic evaluation and treatment
• Rehabilitation and soft-tissue therapy
• Mobility restoration, strengthening, posture and ergonomics
• Imaging when indicated
• Medical co-management and specialist referrals
• Documentation for legal-medical continuity

Goal:

• Control pain while restoring function and minimizing unnecessary long-term opioid exposure

We Treat the Person, Not Just the Pain Score

Functional outcomes matter most:

• Can you sleep?
• Walk and work?
• Family cares?
• Bend, lift, rotate safely?
• Reduce emergency care visits?
• Reduce risky medication use?
• Regain confidence and participate in life again?

The Biopsychosocial Model: Why Context Determines Success

Biological:

• Tissue injury, inflammation, nerve irritation, genetics, sleep, hormones, metabolic health

Psychological:

• Fear, anxiety, depression, trauma history, catastrophizing, coping skills, motivation

Social:

• Work demands, family support, finances, access to care, transportation, legal or injury claims, community safety, stigma

Plans must respect all three.

Language and Stigma: Words Save Lives

I use respectful language:

• Person with opioid use disorder (not addict)
• Return to use (not dirty)
• Medication treatment (not replacement addiction)

Reducing stigma improves trust, disclosure, and safety.

How I Explain Buprenorphine, Methadone, and Naltrexone to Patients

Buprenorphine:

• Sits strongly on the opioid receptor, activates it enough to reduce withdrawal and cravings, with a safety ceiling on breathing suppression relative to full agonists. It is still an opioid and requires careful use, safe storage, and avoidance of sedatives.

Methadone:

• A full agonist in regulated OTP settings; highly effective for withdrawal and cravings but requires structured dosing and monitoring.

Naltrexone:

• Blocks opioid receptors; does not treat withdrawal; requires full detox first; complicates acute opioid pain management.

Integrative Care Does Not Mean Avoiding Medication

I use the right tool at the right time:

• MOUD for OUD
• Chiropractic care for mechanical dysfunction
• Rehabilitation for movement and strength
• Functional medicine for systemic contributors
• Internal medicine oversight for comorbidities
• Harm reduction for safety
• Patient education to build agency

Avoid Abrupt Discontinuation

Stopping opioids or buprenorphine abruptly can cause withdrawal, pain flares, insomnia, cravings, and overdose risk from reduced tolerance. Tapers should be slow, individualized, and collaborative.

Clinical Goals: Safety, Recovery, and Function

I aim to:

• Reduce overdose risk
• Reduce withdrawal and cravings
• Improve pain control safely
• Identify mechanical and systemic pain drivers
• Restore movement and strength
• Improve sleep and metabolic health
• Reduce inflammation
• Improve quality of life
• Coordinate care with medical oversight
• Respect patient autonomy

Practical Comfort Measures During Transitions

To reduce muscle cramps and soreness:

• Warm showers and baths
• Heat therapy and gentle electrotherapy
• Hydration and light mobility drills
• Breathing practices to calm autonomic arousal

These simple measures increase distress tolerance and help patients stay engaged.

Insurance and Access: Building Bridges That Patients Can Walk

We proactively:

• Address insurance barriers and prior authorizations
• Maintain a map of community resources (OTPs, prescribers, ED/urgent care Brixadi programs, harm reduction services)
• Support primary care providers continuing buprenorphine within their scope
• Refer responsibly when necessary and communicate clearly

Administrative competence protects clinical intent.

Monitoring, Check-Ins, and Continuity

We design check-ins around common turning points:

• Days 1–3 of initiation: withdrawal symptoms, sleep, hydration
• End of week with weekly Brixadi: need for supplements if levels dip
• Months 1–3 of Sublocade: counseling on steady state and temporary sublingual supplementation

Consistent communication builds confidence and retention.

Measuring Success: Outcomes That Matter

We track:

• Cravings and withdrawal, dose stability
• Functional gains and return-to-work milestones
• Quality of life (sleep, mood, energy)
• Safety signals (sedation, respiratory risk, QTc changes, adverse events)
• Retention and adherence (doses, injections, follow-up)

Safety Algorithms: How I Decide in Practice

• High fentanyl exposure and need to remain functional: favor low-dose microdosing with comfort measures; consider weekly Brixadi if ED linkage and referral are available.
• Prior precipitated withdrawal or strong fear: low-dose microdosing with clear timelines and monitoring; avoid abrupt displacement.
• QTc >500 ms or significant risk: avoid methadone initiation; consider buprenorphine strategies.
• Active polysubstance use: increase monitoring; emphasize naloxone; phase behavioral supports; avoid sedative co-prescriptions.
• Pregnancy: sublingual buprenorphine; split dosing; avoid injectables; coordinate OB care.
• Perioperative: continue buprenorphine; build multimodal analgesia with anesthesia.

Case Snapshots: How Principles Become Care

• Construction worker with high fentanyl exposure:

• • Low-dose microdosing with comfort kit and daily heat for cramps
  • Initial stabilization at 28–32 mg/day, then transition to Sublocade
  • Chiropractic adjustments restore shoulder mechanics; rehab and functional medicine improve sleep and resilience

• Pregnant patient:

• • Continue sublingual buprenorphine with split dosing
  • Coordinate obstetric care
  • Gentle mobility, breathing drills; stable maternal outcomes

• Adolescent at overdose risk:

• • 8 mg buprenorphine to achieve minimum blockade
  • Family-supported plan and school structure
  • Sleep and digital hygiene coaching

Ethical Framework: Compassion, Clarity, and Agency

• Compassion for lived experiences of pain and trauma
• Clarity in expectations, timelines, and responsibilities
• Agency through shared decision-making, accessible education, and supportive follow-up

Key Takeaways for Patients and Families

• Buprenorphine and methadone are evidence-based, life-saving treatments for OUD.
• Buprenorphine’s partial agonism provides a safety ceiling; methadone requires structured oversight.
• Naltrexone blocks opioids and is not for pain relief; it requires full detox before initiation.
• Buprenorphine can be used for selected pain cases and transitions away from higher-risk regimens.
• Integrative chiropractic care improves mechanics, reduces nociception, and supports function.
• Rehabilitation rebuilds capacity, confidence, and daily function.
• Functional medicine reduces inflammation and improves sleep and metabolic resilience.
• Medical oversight is essential with comorbidities, liver disease, pregnancy, or complex medication histories.
• Harm reduction and naloxone access save lives.
• Stigma-free communication improves safety and trust.

Professional Collaboration at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic)

• I, Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, provide integrative chiropractic, functional medicine, rehabilitation, and personal injury care.
• Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine (NPI #1164426749, Texas MD License #J2933), serves as Medical Director and Collaborative Physician with over 40 years of experience.
• Together, we deliver coordinated, evidence-based, patient-centered care for injury, chronic pain, metabolic issues, and medication-related complexity.

Explore my public educational content and professional profile:

• https://pushasrx.com/
• https://www.linkedin.com/in/dralexjimenez/

References

• Medications for opioid use disorder save lives.

National Academies of Sciences, Engineering, and Medicine. (2019). Medications for opioid use disorder save lives. The National Academies Press. https://doi.org/10.17226/25310

• Medications for opioid use disorder: Treatment Improvement Protocol 63

Substance Abuse and Mental Health Services Administration. (2021). Medications for opioid use disorder: Treatment Improvement Protocol 63.

• CDC clinical practice guideline for prescribing opioids for pain: United States, 2022

Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022). CDC clinical practice guideline for prescribing opioids for pain: United States, 2022. MMWR Recommendations and Reports, 71(3), 1–95. https://doi.org/10.15585/mmwr.rr7103a1

• FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain

U.S. Food and Drug Administration. (2022). FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain.

• Opioid use disorder treatment and mortality reduction

Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ, 357, j1550. https://doi.org/10.1136/bmj.j1550

• ASAM national practice guideline for the treatment of opioid use disorder

American Society of Addiction Medicine. (2020). The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update.

• VA and DoD clinical practice guideline for the use of opioids in the management of chronic pain

Department of Veterans Affairs & Department of Defense. (2022). VA/DoD clinical practice guideline for the use of opioids in the management of chronic pain.

• WHO guidelines for the psychosocially assisted pharmacological treatment of opioid dependence

World Health Organization. (2009). Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence.

• Basic opioid pharmacology: An update

Pathan, H., & Williams, J. (2012). Basic opioid pharmacology: An update. British Journal of Pain, 6(1), 11–16. https://doi.org/10.1177/2049463712438493

• Buprenorphine: A unique drug with complex pharmacology

Lutfy, K., & Cowan, A. (2004). Buprenorphine: A unique drug with complex pharmacology. Current Neuropharmacology, 2(4), 395–402. https://doi.org/10.2174/1570159043359477

• California Bridge. Buprenorphine Quick Start
• Clinical observations and educational materials by Dr. Alexander Jimenez
• Professional profile of Dr. Alexander Jimenez

Note: Several literature items commonly cited in advanced dosing (e.g., dosing up to 32 mg/day for fentanyl-exposed patients) are discussed in guideline updates, clinical considerations, and emergent practice literature within ASAM-aligned frameworks and implementation programs such as California Bridge. Where applicable, we individualize dosing and document the clinical rationale in alignment with safety, stabilization needs, and payer policies.

SEO tags: buprenorphine, methadone, naltrexone, opioid use disorder, OUD, chronic pain, integrative chiropractic care, functional medicine, rehabilitation, personal injury care, precipitated withdrawal, fentanyl era, microdosing buprenorphine, macrodosing buprenorphine, Sublocade, Brixadi, Butrans, Belbuca, buprenorphine dental risks, naloxone access, harm reduction, respiratory depression risk, benzodiazepines and opioids, QTc monitoring methadone, perioperative buprenorphine, pregnancy buprenorphine, adolescent buprenorphine, central sensitization, opioid-induced hyperalgesia, mu-opioid receptor, shared decision-making, multidisciplinary clinic, El Paso chiropractor, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, Dr Alex Jimenez, Dr Maria Guadalupe Cardenas MD